TY - JOUR
T1 - Minimally invasive versus open liver resection for nonmetastatic hepatocellular carcinoma staged BCLC – B and – C
T2 - an Italian multicentric analysis
AU - for the HE.RC.O.LE.S. study group
AU - Cassese, Gianluca
AU - C. Giglio, Mariano
AU - Vitale, Alessandro
AU - Lauterio, Andrea
AU - Serenari, Matteo
AU - Cipriani, Federica
AU - Ardito, Francesco
AU - Perri, Pasquale
AU - Nicolini, Daniele
AU - Di Gioia, Giulio
AU - Fontana, Andrea Pierluigi
AU - Lai, Quirino
AU - Conci, Simone
AU - Fumagalli, Luca
AU - Iaria, Maurizio
AU - Garancini, Mattia
AU - Molfino, Sarah
AU - Zanello, Matteo
AU - La Barba, Giuliano
AU - Conticchio, Maria
AU - Germani, Paola
AU - Famularo, Simone
AU - Romano, Maurizio
AU - Zimmitti, Giuseppe
AU - De Angelis, Michela
AU - Troci, Albert
AU - Belli, Andrea
AU - Izzo, Francesco
AU - Crespi, Michele
AU - Boccia, Luigi
AU - Abu Hilal, Mohamed
AU - Zanus, Giacomo
AU - Torzilli, Guido
AU - Tarchi, Paola
AU - Memeo, Riccardo
AU - Ercolani, Giorgio
AU - Jovine, Elio
AU - Baiocchi, Gianluca
AU - Romano, Fabrizio
AU - Della Valle, Raffaele
AU - Chiarelli, Marco
AU - Ruzzenente, Andrea
AU - Rossi, Massimo
AU - Ferrero, Alessandro
AU - Maestri, Marcello
AU - Vivarelli, Marco
AU - Grazi, Gian Luca
AU - Giuliante, Felice
AU - Aldrighetti, Luca
AU - Donadon, Matteo
N1 - Publisher Copyright:
© 2025 International Hepato-Pancreato-Biliary Association Inc.
PY - 2025
Y1 - 2025
N2 - Background: Recent papers report significant survival gain after liver resection in BCLC-B and -C HCC patients. The results of minimally invasive liver surgery (MILS) in such patients have not been widely investigated so far. Methods: Data regarding patients undergoing MILS or open liver resection (OLR) for HCC staged BCLC -B and -C were extracted from the HERCOLES database. An inverse probability of treatment weighting (IPTW) method was adopted to balance the confounders. The primary outcome was a composite endpoint including post-hepatectomy liver failure, severe postoperative complications and in-hospital mortality. Results: 627 patients were included (459 undergoing OLR and 168 receiving MILS). After IPTW, no difference was found in the composite endpoint between MILS and OLR (OR 0.86 [95%CI 0.46-1-60]; p = 0.62). MILS reduced the risk of receiving intra-operative transfusions (OR 0.28 [95%CI 0.13-0.58]; p < 0.001) and of developing postoperative ascites (OR 0.56 [95%CI 0,32-0,98]; p = 0.039), with reduced length of stay (OR 0.82 [95%CI 0.66-1.01]; p = 0.045). The survival analysis showed no differences between MILS and OLR for both OS (p = 0.13) and DFS (p = 0.491). Conclusion: MILS was shown to be safe and feasible for selected non-metastatic HCC patients staged BCLC B and C, reducing the risk of perioperative transfusions and postoperative ascites, and shortening the length of stay.
AB - Background: Recent papers report significant survival gain after liver resection in BCLC-B and -C HCC patients. The results of minimally invasive liver surgery (MILS) in such patients have not been widely investigated so far. Methods: Data regarding patients undergoing MILS or open liver resection (OLR) for HCC staged BCLC -B and -C were extracted from the HERCOLES database. An inverse probability of treatment weighting (IPTW) method was adopted to balance the confounders. The primary outcome was a composite endpoint including post-hepatectomy liver failure, severe postoperative complications and in-hospital mortality. Results: 627 patients were included (459 undergoing OLR and 168 receiving MILS). After IPTW, no difference was found in the composite endpoint between MILS and OLR (OR 0.86 [95%CI 0.46-1-60]; p = 0.62). MILS reduced the risk of receiving intra-operative transfusions (OR 0.28 [95%CI 0.13-0.58]; p < 0.001) and of developing postoperative ascites (OR 0.56 [95%CI 0,32-0,98]; p = 0.039), with reduced length of stay (OR 0.82 [95%CI 0.66-1.01]; p = 0.045). The survival analysis showed no differences between MILS and OLR for both OS (p = 0.13) and DFS (p = 0.491). Conclusion: MILS was shown to be safe and feasible for selected non-metastatic HCC patients staged BCLC B and C, reducing the risk of perioperative transfusions and postoperative ascites, and shortening the length of stay.
UR - http://www.scopus.com/inward/record.url?scp=85217981977&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2025.01.009
DO - 10.1016/j.hpb.2025.01.009
M3 - Article
SN - 1365-182X
JO - HPB
JF - HPB
ER -